Skip to main content
Fig. 2 | Parasites & Vectors

Fig. 2

From: Onchocerca volvulus microfilariae in the anterior chambers of the eye and ocular adverse events after a single dose of 8 mg moxidectin or 150 µg/kg ivermectin: results of a randomized double-blind Phase 3 trial in the Democratic Republic of the Congo, Ghana and Liberia

Fig. 2

mfAC 4 days, 1, 6, 12 and 18 months post-treatment relative to pre-treatment mfAC among participants with ≥ 10 mfAC pre-treatment. x-axis mfAC levels pre-treatment, y-axis mfAC levels on Day 4 (D4 1st column), Month 1 (M1 2nd column), Month 6 (M6, 3rd column), Month 12 (M12 4th column) and Month 18 (M18, 5th column) post-treatment with ivermectin (IVM, upper row, orange symbols) or moxidectin (Moxi, lower row, green symbols). Data from participants from Nord Kivu (∆), Nord Ituri (○), Lofa County (□) and Nkwanta district (◊). mfAC live microfilariae in the anterior chambers

Back to article page

Parasites & Vectors

ISSN: 1756-3305

Contact us